A new tuberculosis vaccine has been developed by researchers. The new vaccine was developed to act as a booster to Bacille Calmette Guerin (BCG), currently the only TB vaccine available.
The vaccine, based on a genetically modified cold virus, was developed in the lab of Zhou Xing, professor of pathology and molecular medicine and the McMaster Immunology Research Centre, who co-led the phase one study with Dr. Fiona Smaill, professor and chair of the Department of Pathology and Molecular Medicine of the Michael G. DeGroote School of Medicine at McMaster.
BCG was developed in the 1920s and has been used worldwide. The new "booster" would reactivate immune elements that over time diminish following BCG vaccination.
The findings have been published in the journal Science Translational Medicine.